ADC Therapeutics Total Revenue Over Time

ADCT Stock  USD 2.26  0.04  1.80%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ADC Therapeutics Performance and ADC Therapeutics Correlation.
  
Total Revenue is likely to drop to about 50.1 M in 2024.
Is Communications Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADC Therapeutics. If investors know ADC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.39)
Revenue Per Share
0.774
Quarterly Revenue Growth
0.274
Return On Assets
(0.21)
Return On Equity
(7.06)
The market value of ADC Therapeutics is measured differently than its book value, which is the value of ADC that is recorded on the company's balance sheet. Investors also form their own opinion of ADC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ADC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADC Therapeutics' market value can be influenced by many factors that don't directly affect ADC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Total Revenue Analysis

Compare ADC Therapeutics and related stocks such as Passage Bio, Black Diamond Therap, and Tcr2 Therapeutics Total Revenue Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
PASG0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
BDTX0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
ALEC416 K416 K416 K416 K416 K416 K416 K3.7 M27.7 M21.2 M21.1 M207.1 M133.6 M97.1 M70.4 M
IPSC950.8 M950.8 M950.8 M950.8 M950.8 M950.8 M470.3 M0.00.00.00.01.1 M5.2 M2.2 M2.1 M
GBIO36 K36 K36 K36 K36 K36 K36 K36 K36 K0.00.00.0880 K5.9 M6.2 M
STOK0.00.00.00.00.00.00.00.00.00.00.0M12.4 M8.8 M9.2 M
RARE0.00.00.00.00.00.0133 K2.6 M51.5 M103.7 M271 M351.4 M363.3 M434.2 M456 M
CRNX589 K589 K589 K589 K589 K589 K589 KM2.4 M1.2 M71 K1.1 M4.7 MM2.2 M
ARVN6.7 M6.7 M6.7 M6.7 M6.7 M6.7 M6.7 M7.6 M14.3 M43 M21.8 M46.7 M131.4 M78.5 M48.1 M
RVMD0.00.00.00.00.00.00.00.020.2 M50 M43 M29.4 M35.4 M11.6 M11 M
KURA0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
AKRO0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
RNA11.3 M11.3 M10.4 M13.1 M379 K379 K379 K379 K379 K2.3 M6.8 M9.3 M9.2 M9.6 M6.4 M
PTGX0.00.00.00.00.00.00.020.1 M30.9 M231 K28.6 M27.4 M26.6 M60 M63 M
DSGN834 K834 K834 K834 K834 K834 K834 K834 K834 K834 K2260.00.00.00.0
ALXO2.1 M2.1 M2.1 M2.1 M2.1 M2.1 M2.1 M2.1 M2.1 M4.8 M1.2 M0.00.00.00.0
AADI20.2 M20.2 M20.2 M20.2 M20.2 M20.2 M20.2 M20.2 M20.2 M749 K14 M1000 K15.2 M24.4 M13.8 M
ALVR1.1 M1.1 M1.1 M1.1 M1.1 M1.1 M1.1 M1.1 M1.1 M165 K0.00.00.00.00.0

ADC Therapeutics and related stocks such as Passage Bio, Black Diamond Therap, and Tcr2 Therapeutics Total Revenue description

Total revenue comprises all receipts ADC Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

My Equities

My Current Equities and Potential Positions

ADC Therapeutics SA
ADCT
Specialization
Information Technology, Technology Hardware & Equipment
LocationSwitzerland
ExchangeNew York Stock Exchange
USD 2.26

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.